|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACTR3B |
Gene summary for ACTR3B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACTR3B | Gene ID | 57180 |
| Gene name | actin related protein 3B | |
| Gene Alias | ARP11 | |
| Cytomap | 7q36.1-q36.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q59GD5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57180 | ACTR3B | LZE24T | Human | Esophagus | ESCC | 3.61e-06 | 1.47e-01 | 0.0596 |
| 57180 | ACTR3B | P2T-E | Human | Esophagus | ESCC | 9.14e-08 | 1.12e-01 | 0.1177 |
| 57180 | ACTR3B | P4T-E | Human | Esophagus | ESCC | 8.38e-15 | 2.42e-01 | 0.1323 |
| 57180 | ACTR3B | P5T-E | Human | Esophagus | ESCC | 3.55e-07 | 1.47e-01 | 0.1327 |
| 57180 | ACTR3B | P8T-E | Human | Esophagus | ESCC | 4.70e-07 | 5.65e-02 | 0.0889 |
| 57180 | ACTR3B | P9T-E | Human | Esophagus | ESCC | 2.14e-05 | 1.18e-01 | 0.1131 |
| 57180 | ACTR3B | P10T-E | Human | Esophagus | ESCC | 3.52e-16 | 2.46e-01 | 0.116 |
| 57180 | ACTR3B | P12T-E | Human | Esophagus | ESCC | 4.05e-19 | 3.13e-01 | 0.1122 |
| 57180 | ACTR3B | P15T-E | Human | Esophagus | ESCC | 4.60e-14 | 3.25e-01 | 0.1149 |
| 57180 | ACTR3B | P16T-E | Human | Esophagus | ESCC | 2.68e-50 | 1.02e+00 | 0.1153 |
| 57180 | ACTR3B | P17T-E | Human | Esophagus | ESCC | 2.07e-03 | 1.26e-01 | 0.1278 |
| 57180 | ACTR3B | P20T-E | Human | Esophagus | ESCC | 4.89e-05 | 1.21e-01 | 0.1124 |
| 57180 | ACTR3B | P21T-E | Human | Esophagus | ESCC | 3.01e-08 | 1.49e-01 | 0.1617 |
| 57180 | ACTR3B | P22T-E | Human | Esophagus | ESCC | 1.15e-04 | 4.51e-02 | 0.1236 |
| 57180 | ACTR3B | P23T-E | Human | Esophagus | ESCC | 9.63e-06 | 1.10e-01 | 0.108 |
| 57180 | ACTR3B | P24T-E | Human | Esophagus | ESCC | 5.92e-05 | 9.49e-02 | 0.1287 |
| 57180 | ACTR3B | P26T-E | Human | Esophagus | ESCC | 1.31e-11 | 1.48e-01 | 0.1276 |
| 57180 | ACTR3B | P27T-E | Human | Esophagus | ESCC | 8.97e-14 | 2.23e-01 | 0.1055 |
| 57180 | ACTR3B | P28T-E | Human | Esophagus | ESCC | 8.36e-09 | 1.36e-01 | 0.1149 |
| 57180 | ACTR3B | P30T-E | Human | Esophagus | ESCC | 2.05e-06 | 1.84e-01 | 0.137 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
| hsa0513526 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
| hsa05100211 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
| hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
| hsa0466620 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
| hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
| hsa05135111 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
| hsa05100310 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
| hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
| hsa04666110 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
| hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACTR3B | SNV | Missense_Mutation | c.140N>G | p.Ala47Gly | p.A47G | Q9P1U1 | protein_coding | tolerated(0.53) | benign(0.05) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ACTR3B | SNV | Missense_Mutation | rs771304758 | c.491N>T | p.Thr164Met | p.T164M | Q9P1U1 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-B6-A0I2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ACTR3B | SNV | Missense_Mutation | c.1153G>A | p.Ala385Thr | p.A385T | Q9P1U1 | protein_coding | deleterious(0.02) | benign(0.393) | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ACTR3B | SNV | Missense_Mutation | novel | c.175N>A | p.Asp59Asn | p.D59N | Q9P1U1 | protein_coding | deleterious(0.04) | benign(0.243) | TCGA-BH-AB28-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| ACTR3B | insertion | Frame_Shift_Ins | novel | c.1013_1014insGGGGGAGCATGAGGGAGCAGGATCGCCTTGTT | p.Asp338GlufsTer13 | p.D338Efs*13 | Q9P1U1 | protein_coding | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | ||
| ACTR3B | SNV | Missense_Mutation | novel | c.1225N>T | p.Arg409Cys | p.R409C | Q9P1U1 | protein_coding | deleterious(0.02) | probably_damaging(0.985) | TCGA-VS-A8EG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ACTR3B | SNV | Missense_Mutation | c.1061N>A | p.Ser354Asn | p.S354N | Q9P1U1 | protein_coding | deleterious(0.02) | benign(0.316) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACTR3B | SNV | Missense_Mutation | rs777288190 | c.709G>A | p.Asp237Asn | p.D237N | Q9P1U1 | protein_coding | deleterious(0.05) | benign(0.182) | TCGA-CA-6715-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
| ACTR3B | SNV | Missense_Mutation | c.853N>A | p.Pro285Thr | p.P285T | Q9P1U1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CM-6168-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACTR3B | SNV | Missense_Mutation | c.493N>T | p.Gly165Trp | p.G165W | Q9P1U1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-DM-A28A-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |